© Pradipat Wongkasetin
“This strategic acquisition will not only bolster our existing portfolio but also pave the way for new market opportunities, and most importantly, to protect our strain security with another genetic nucleus and broodstock multiplication facility in the USA,” the company stated in a press release.
Primo has a strong legacy, according to SyAqua, as the first genetics company to use SPF vannamei populations out of Ecuador to address disease challenges in major markets like Mexico and China.
“This acquisition allows us to tap into robust and well-established genetic resources while significantly expanding our US genetic nucleus and broodstock multiplication facilities,” stated SyAqua.
“SyAqua now has the potential to tap new genetic stocks developed over years of selective breeding for disease tolerance. This strategic move opens potential for more innovative selection strategies that will bring our customers enhanced performance even in the most challenging production environments. We anticipate a significant increase in supply of our US broodstock production capacity by the end of 2024, targeting potential production of more than 230,000 broodstock per year,” they add.
Meanwhile SyAqua says that it is continuing to refine its biofloc-based raceway production technologies.
As the company stated: “The acquisition of Primo enriches our genetic resources, aligning with our vision of business sustainability and our commitment to managing environmental impact of the blue economy, particularly in Asian shrimp farming.
“Furthermore, our alliance with Ocean 14 Capital Fund strengthens our dedication to sustainable practices and innovative solutions in aquaculture.”
